Cargando…
Disease-modifying effects of a glial-targeted inducible nitric oxide synthase inhibitor (1400W) in mixed-sex cohorts of a rat soman (GD) model of epilepsy
BACKGROUND: Acute exposure to seizurogenic organophosphate (OP) nerve agents (OPNA) such as diisopropylfluorophosphate (DFP) or soman (GD), at high concentrations, induce immediate status epilepticus (SE), reactive gliosis, neurodegeneration, and epileptogenesis as a consequence. Medical countermeas...
Autores principales: | Vasanthi, Suraj S., Rao, Nikhil S., Samidurai, Manikandan, Massey, Nyzil, Meyer, Christina, Gage, Meghan, Kharate, Mihir, Almanza, Aida, Wachter, Logan, Mafuta, Candide, Trevino, Lily, Carlo, Adriana M., Bryant, Elijah, Corson, Brooke E., Wohlgemuth, Morgan, Ostrander, Morgan, Showman, Lucas, Wang, Chong, Thippeswamy, Thimmasettappa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10337207/ https://www.ncbi.nlm.nih.gov/pubmed/37438764 http://dx.doi.org/10.1186/s12974-023-02847-1 |
Ejemplares similares
-
Disease-Modifying Effects of a Glial-targeted Inducible Nitric Oxide Synthase Inhibitor (1400W) in Mixed-sex Cohorts of a Rat Soman (GD) Model of Epilepsy
por: Vasanthi, Suraj S., et al.
Publicado: (2023) -
1400 W, a selective inducible nitric oxide synthase inhibitor, mitigates early neuroinflammation and nitrooxidative stress in diisopropylfluorophosphate-induced short-term neurotoxicity rat model
por: Massey, Nyzil, et al.
Publicado: (2023) -
DFP-Induced Status Epilepticus Severity in Mixed-Sex Cohorts of Adult Rats Housed in the Same Room: Behavioral and EEG Comparisons
por: Rao, Nikhil S., et al.
Publicado: (2022) -
Soman (GD) Rat Model to Mimic Civilian Exposure to Nerve Agent: Mortality, Video-EEG Based Status Epilepticus Severity, Sex Differences, Spontaneously Recurring Seizures, and Brain Pathology
por: Gage, Meghan, et al.
Publicado: (2022) -
Exploring the benefits of in-diet versus repeated oral dosing of saracatinib (AZD0530) in chronic studies: insights into pharmacokinetics and animal welfare
por: Vasanthi, Suraj S., et al.
Publicado: (2023)